{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"84.7","upperLimit":"93.5","value":"89.1"},{"groupId":"OG001","lowerLimit":"87.8","upperLimit":"92.5","value":"90.2"},{"groupId":"OG002","lowerLimit":"84.6","upperLimit":"90.1","value":"87.4"},{"groupId":"OG003","lowerLimit":"85.4","upperLimit":"91.0","value":"88.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"91"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"102"}],"units":"Participants"}],"description":"The MDADI measures swallowing-related quality of life (QOL) in patients with swallowing dysfunction in a 20-item written questionnaire. It evaluates the patient's physical (P), emotional (E) and functional (F) perceptions of swallowing dysfunction. This instrument has been psychometrically validated in head and neck cancer patients. Two summary scores can be obtained from the MDADI: 1) global and 2) composite. The global scale is a single question, scored individually, to assess the overall impact that swallowing abilities have on quality of life (\"my swallowing impacts my day-to-day life\"). The composite MDADI score summarizes overall performance on remaining 19-items of the MDADI, as a weighted average of the physical, emotional, and functional subscale questions. This study reports the composite MDADI score. The summary MDADI scores are normalized to range from 20 (extremely low functioning) to 100 (high functioning).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, low risk patients are under observation.","id":"OG000","title":"Arm S (Surgery) Then Arm A (Low Risk, Observation)"},{"description":"Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, intermediate risk patients receive low-dose IMRT (50 Gy) QD five days a week for 5 weeks.","id":"OG001","title":"Arm S (Surgery) Then Arm B (Intermediate Risk, Low-dose IMRT)"},{"description":"Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, intermediate risk patients receive standard-dose IMRT (60 Gy) QD five days a week for 6 weeks.","id":"OG002","title":"Arm S (Surgery) Then Arm C (Intermediate Risk, Standard-dose IMRT)"},{"description":"Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, high risk patients then receive IMRT (66Gy) QD five days a week for 6-7 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiation therapy.","id":"OG003","title":"Arm S (Surgery) Then Arm D (High Risk, IMRT, Chemotherapy)"}],"paramType":"MEAN","populationDescription":"Eligible and treated patients with baseline MDADI scores available","reportingStatus":"POSTED","timeFrame":"Assessed at baseline","title":"Swallowing Function Before Surgery Assessed Using MD Anderson Dysphagia Inventory (MDADI)","type":"SECONDARY","unitOfMeasure":"score on a scale"}